Published in Drug Law Weekly, October 4th, 2005
The letter provides that Dacogen injection is approvable pending the FDA's review of a requested analysis of the transfusion requirements of patients enrolled in the completed phase III trial, submission of certain other information, and completion of labeling discussions.
"We are working diligently to complete the requested analysis of data and provide this information to the FDA as early as possible during...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.